Clinical Outcomes After Apparent Clinical Events Without Radiological Signs ( ACES ) in Relapsing–Remitting Multiple Sclerosis: A Retrospective Cohort Study
Clinical and Experimental Neuroimmunology · 2026-11 · 17 (4)
DOI: 10.1111/cen3.70089 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Experimental Neuroimmunology, online erschienen am 13.11.2026. Verfasst von Gabriela Abrahão Allioni und 11 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Clinical relapses in multiple sclerosis (MS) can occur without detectable inflammatory activity, termed apparent clinical events without radiological signs (ACES). The subsequent evolution of disability and inflammatory disease activity after ACES remains poorly characterized.
Objectives
To compare disability progression and subsequent clinical and radiological inflammatory activity in MS patients presenting with ACES versus relapses with active MRI (RAM).
Methods
Retrospective observational study including consecutive MS patients evaluated at a tertiary MS center in Brazil. Relapses were classified as ACES or relapses with active MRI (RAM) based on the presence of new T2/FLAIR or gadolinium‐enhancing lesions. Expanded Disability Status Scale (EDSS) at 6–12 and 24 months, clinical and radiological activity over two years were compared between groups.
Results
Among 54 patients, 25 (46%) presented with ACES and 29 (54%) with RAM. Patients with ACES were significantly older at relapse onset. Baseline disability, disease duration, functional system involvement, and disease‐modifying therapy use showed no statistically significant between‐group differences. EDSS at 6–12 and 24 months, 2‐year clinical relapse rates, and MRI activity also showed no statistically significant differences between ACES and RAM.
Conclusions
ACES were common and occurred predominantly in older patients with relapsing–remitting MS. Over 2 years, no statistically significant differences were observed in disability outcomes, clinical relapse rates, or radiological activity between ACES and RAM. Given the limited sample size, clinically meaningful differences cannot be excluded, and larger prospective studies are needed to clarify the long‐term significance of ACES.
Zitieren
APA
Allioni, G. A., Sales, A. B. L., Veiga, M. L., Santana, J. L. S., Bernal, H. D. M., Marzano, L. A. S., Spricigo, M. G., Oliveira, M. B. D., Pereira, S. L. D. A., Adoni, T., Callegaro, D., & Silva, G. D. (2026). Clinical Outcomes After Apparent Clinical Events Without Radiological Signs ( ACES ) in Relapsing–Remitting Multiple Sclerosis: A Retrospective Cohort Study. Clinical and Experimental Neuroimmunology, 17(4). https://doi.org/10.1111/cen3.70089
Vancouver
Allioni GA, Sales ABL, Veiga ML, Santana JLS, Bernal HDM, Marzano LAS, et al. Clinical Outcomes After Apparent Clinical Events Without Radiological Signs ( ACES ) in Relapsing–Remitting Multiple Sclerosis: A Retrospective Cohort Study. Clinical and Experimental Neuroimmunology. 2026;17(4). doi:10.1111/cen3.70089
BibTeX
@article{Allioni2026,
author = {Allioni, Gabriela Abrahão and Sales, Alana Bacelar Limeira and Veiga, Milena Lins and Santana, João Lucas Silva and Bernal, Henrique de Moraes and Marzano, Lucas Alexandre Santos and Spricigo, Mariana Gondim and Oliveira, Mateus Boaventura de and Pereira, Samira Luisa dos Apostolos and Adoni, Tarso and Callegaro, Dagoberto and Silva, Guilherme Diogo},
title = {Clinical Outcomes After Apparent Clinical Events Without Radiological Signs ( ACES ) in Relapsing–Remitting Multiple Sclerosis: A Retrospective Cohort Study},
journal = {Clinical and Experimental Neuroimmunology},
year = {2026},
volume = {17},
number = {4},
doi = {10.1111/cen3.70089}
}
EUVIMED